Drug intelligence / Profile preview

fentanyl + sevoflurane

Development stage
Unknown
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Intravenous, Inhalation
01

Overview

Fentanyl + sevoflurane is a combination of two anesthetic agents used together to induce and maintain general anesthesia, particularly in surgical settings. Fentanyl is a potent synthetic opioid analgesic that acts primarily as a mu-opioid receptor agonist, providing strong pain relief and sedation[6][8]. Sevoflurane is a volatile halogenated inhalational anesthetic that induces unconsciousness by modulating multiple ligand-gated ion channels in the central nervous system, including potentiation of GABA(A) and glycine receptors and inhibition of excitatory neurotransmitter receptors such as glutamate and nicotinic acetylcholine receptors[7]. When combined, fentanyl reduces the minimum alveolar concentration (MAC) required for sevoflurane to achieve anesthesia, allowing for lower doses of sevoflurane while maintaining effective anesthesia. This combination can improve induction conditions, reduce aversive behaviors at induction, shorten induction time, and provide synergistic analgesia; however, it may also increase the risk of respiratory depression or other adverse effects if not carefully monitored[1][2].

Other names
fentanyl + sevoflurane-Centre Hospitalier Universitaire Vaudoisfentanyl and sevofluranefentanyl-sevoflurane regimen
02

Targets

GABRR (GABA-A receptor subunit rho)Glycine receptorNMDAR (Glutamate receptor ionotropic, NMDA)DOR (Opioid Receptor Delta 1)Nicotinic Acetylcholine ReceptorMOR (Mu opioid receptor)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on fentanyl + sevoflurane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fentanyl + sevoflurane.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call